101.65 -1.00 (-0.97%)
Pre-Market: 8:19AM EST
|Bid||101.35 x 200|
|Ask||101.88 x 100|
|Day's Range||102.00 - 103.05|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||24.06|
|Earnings Date||Jan 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||124.29|
Celgene inks the Summit, N.J.-based group's biggest-ever takeover with a $9 billion play for cancer treatment specialist biotech Juno Therapeutics.
Celgene will acquire Juno Therapeutics for $9 billion. Sanofi reached a deal Monday to buy hemophilia drugmaker Bioverativ for $11.6 billion, or $105 a share.
Celgene said it agreed to buy Juno Therapeutics for $87 a share in cash, or about $9 billion, in a move that will expand Celgene’s portfolio of blood-cancer drugs.
Celgene Corp. on Monday said it's reached a deal to buy Juno Therapeutics Inc., a biotech company developing cancer treatments, for $9 billion, or $87 a share in cash. Juno shares in premarket trade Monday ...
Celgene Corp. agreed to buy Juno Therapeutics Inc. for about $9 billion, one of its largest deals ever, in a bid to expand in the increasingly competitive landscape of cutting-edge cancer treatments.
Celgene Corporation and Juno Therapeutics, Inc. today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.
Celgene Corporation today announced primary endpoint findings and updated results of secondary endpoints from the phase II international LAPACT trial of ABRAXANE® plus gemcitabine in patients with locally advanced pancreatic cancer.
Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.
The earnings season will get its first taste of results from Silicon Valley, led by Netflix, Intel and other chip companies.
The biopharmaceutical company, whose biggest acquisition to date was Receptos in 2015 for $7.2 billion, recently agreed to pay up to $7 billion for Impact Biomedicines and reportedly is in talks for Juno, ...
M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG ) is pursuing Juno Therapeutics ...
Celgene Corp. (NASDAQ:CELG), best known for the psoriasis medicine Otezla and a number of cancer drugs, like Revlimid and Vidaza, sent the stock of Juno Therapeutics Inc. (NASDAQ:JUNO) up 55% on Jan. 17 when it was reported to be buying it. An acquisition probably won’t change a lot for CELG stock. The rumored price for Juno would be $10-12 billion, not a big deal when Celgene is worth $80 billion, but Juno was only worth $5.6 billion on Jan. 12.
Depositary shares of the up-and-coming Chinese biotech firm BeiGene (BGNE) jumped 15% today, to $118, after the company successfully raised $750 million in a follow-on share offering. BeiGene has promising drugs under development, ample funding, and international partners like Celgene (CELG) and Boehringer Ingelheim. The Beijing-based drug developer is one of China’s leading hopes as that country tries to become one of the world’s medical innovators.